A Comparison of Efficacy and Safety of Two Lipid-Based Lubricant Eye Drops for the Management of Evaporative Dry Eye Disease

被引:14
|
作者
Jerkins, Gary [1 ]
Greiner, Jack, V [2 ,3 ]
Tong, Louis [4 ,5 ,6 ]
Tan, Jacqueline [7 ]
Tauber, Joseph [8 ]
Mearza, Ali [9 ,10 ]
Srinivasan, Sruthi [11 ]
机构
[1] Adv Vis Res LLC, Nashville, TN 37205 USA
[2] Clin & & Res Boston, Boston, MA USA
[3] Harvard Med Sch, Dept Ophthalmol, Boston, MA 02115 USA
[4] Natl Univ Singapore, Singapore Natl Eye Ctr, Singapore, Singapore
[5] Singapore Eye Res Inst, Singapore, Singapore
[6] Duke Natl Univ, Singapore Med Sch, Singapore, Singapore
[7] Univ New South Wales, Sydney, NSW, Australia
[8] Tauber Eye Ctr, Kansas City, MO USA
[9] Imperial Coll Healthcare NHS Trust, London, England
[10] Ophthalm Consultants London, London, England
[11] Alcon Res LLC, Johns Creek, GA USA
来源
CLINICAL OPHTHALMOLOGY | 2020年 / 14卷
关键词
dry eye; lipid-deficient; evaporative dry eye; lubricant eye drops; non-inferiority; ARTIFICIAL TEARS; MULTICENTER; DEFICIENT; EMULSION; LAYER;
D O I
10.2147/OPTH.S256351
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: The aim of this study was to compare the efficacy of two lipid-based lubricant eye drops in patients with lipid-deficient dry eye. Methods: This Phase IV, multicenter, prospective, double-masked study enrolled adults (aged >= 18 years) who had a tear film breakup time (TFBUT) of <= 15 seconds(s), and unanesthetized Schirmer I test of >= 3 mm to <= 12 mm in at least one eye, at both screening and baseline visits. Eligible patients (n=231) were randomized (1:1) and received either Systane (R) Balance (SYSB; n=117) or Refresh (R) Optive Advanced (RFO-Ad, n=114), four-times a day, for 35 days. The primary endpoint was non-inferiority for change from baseline in TFBUT at Day 35 (noninferiority was established if the lower limit of the 95% confidence interval (CI) for the difference between the treatment groups was > -1.0 s); secondary endpoints (test of superiority) were change in TFBUTand global ocular discomfort visual analog scale (VAS) score at Day 35. Other endpoints included the impact of dry eye on everyday life (IDEEL) treatment satisfaction scores (inconvenience and effectiveness) and safety. Results: At Day 35, themean change from baseline in TFBUTwas 0.998 s in the SYSB and 0.868 s in the RFO-Ad groups with a treatment difference: 0.130 s; (95% CI -0.34, 0.60; P<0.0001) demonstrating non-inferiority of SYSB to RFO-Ad. The global ocular discomfort VAS scores improved in both groups, with a mean change from baseline of -9.7 and -8.8 in SYSB and RFOAd groups (treatment difference -0.8; P=0.62), respectively. No meaningful difference was observed in IDEEL treatment effectiveness and treatment inconvenience scores between SYSB vs RFO-Ad (P>0.05 for treatment difference). Both treatments were well tolerated. Conclusion: SYSB lubricant eye drops were non-inferior to RFO-Ad for improvement in TFBUT in patients with lipid-deficient dry eye. Both lubricant eye drops improved TFBUT and ocular discomfort scores in patients with lipid-deficient dry eye.
引用
收藏
页码:1665 / 1673
页数:9
相关论文
共 50 条
  • [31] Safety and efficacy of a hydroxypropyl guar/polyethylene glycol/propylene glycol-based lubricant eye-drop in patients with dry eye
    Labetoulle, Marc
    Messmer, Elisabeth M.
    Pisella, Pierre-Jean
    Ogundele, Abayomi
    Baudouin, Christophe
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2017, 101 (04) : 487 - 492
  • [32] Frequency of efficacy of topical cyclosporine 0.05% eye drops in the management of dry eyes
    Khalid, Muhammad
    Rizwan, Muhammad
    Khurshid, Sameera
    PAKISTAN JOURNAL OF MEDICAL & HEALTH SCIENCES, 2021, 15 (06): : 1384 - 1386
  • [33] Clinical evaluation of the efficacy of PEG/PG lubricant eye drops with gelling agent (HP-GUAR) for the relief of the signs and symptoms of dry eye disease: A review
    Foulks, Gary N.
    DRUGS OF TODAY, 2007, 43 (12) : 887 - 896
  • [34] A randomized clinical evaluation of the safety of Systane((R)) Lubricant Eye Drops for the relief of dry eye symptoms following LASIK refractive surgery
    Durrie, Daniel
    Stahl, Jason
    CLINICAL OPHTHALMOLOGY, 2008, 2 (04): : 973 - 979
  • [35] Two-Year Progression of Dry Eye Disease in Dry Eye Assessment and Management Study
    Lee, Daniel Chein
    Guo, Michelle
    Yu, Yinxi
    Bunya, Vatinee Y.
    Asbell, Penny
    Ying, Gui-Shuang
    CORNEA, 2024, 43 (10) : 1231 - 1237
  • [36] Randomized, Multicenter, Double-Blind Study of the Safety and Efficacy of 1% D-3-Hydroxybutyrate eye drops for Dry Eye Disease
    Kawakita, Tetsuya
    Uchino, Miki
    Fukagawa, Kazumi
    Yoshino, Kenichi
    Shimazaki, Seika
    Toda, Ikuko
    Tanaka, Mari
    Arai, Hiroyuki
    Sakatani, Keiko
    Hata, Seiichiro
    Okano, Takashi
    Tsubota, Kazuo
    SCIENTIFIC REPORTS, 2016, 6
  • [37] Efficacy of topical bevacizumab 0.05% eye drops in dry eye disease: A double-masked, randomized trial
    Kasetsuwan, Ngamjit
    Chantaralawan, Kanawat
    Reinprayoon, Usanee
    Uthaithammarat, Lita
    PLOS ONE, 2020, 15 (06):
  • [38] Efficacy of a propylene glycol/hydroxypropyl guar-based lubricant eye drop in improving tear stability in patients with dry eye disease
    Srinivasan, Sruthi
    Jones, Lyndon William
    Schulze, Marc-Matthias
    Guillon, Michel
    Tauber, Joseph
    Silverstein, Steven
    Yeu, Elizabeth
    Venkiteshwar, Manoj
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2020, 61 (07)
  • [39] Efficacy and safety of indomethacin 0.1% eye drops compared with ketorolac 0.5% eye drops in the management of ocular inflammation after cataract surgery
    Weber, Michel
    Kodjikian, Laurent
    Kruse, Friedrich E.
    Zagorski, Zbigniew
    Allaire, Catherine M.
    ACTA OPHTHALMOLOGICA, 2013, 91 (01) : e15 - e21
  • [40] Metabolomics comparison of cord and peripheral blood-derived serum eye drops for the treatment of dry eye disease
    Quartieri, Eleonora
    Marraccini, Chiara
    Merolle, Lucia
    Pulcini, Stefano
    Buzzi, Marina
    Guardi, Manuela
    Schiroli, Davide
    Baricchi, Roberto
    Pertinhez, Thelma A.
    TRANSFUSION AND APHERESIS SCIENCE, 2021, 60 (04)